drugset / Trial / NCT02756364
Sapanisertib in Combination With Fulvestrant in Women With Advanced or Metastatic Breast Cancer After Aromatase Inhibitor Therapy
RandomizedParallel-groupOpen-labelTreatment
Summary
The primary purpose of this study is to compare the progression free survival (PFS) of participants treated with the combination of fulvestrant plus daily sapanisertib and fulvestrant plus weekly sapanisertib versus participants treated with single-agent fulvestrant.
Timeline
- Start
- 2016-07-28
- Primary completion
- 2019-11-25
- Completion
- 2019-11-25
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Fulvestrant | Small molecule | 500 mg | Intramuscular |
| Subject | Sapanisertib | Small molecule | 4 mg | Oral |
| Subject | Sapanisertib | Small molecule | 30 mg | Oral |